Ultragenyx Pharmaceutical Stock Price

-0.40 (-0.38%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Ultragenyx Pharmaceutical Inc RARE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.40 -0.38% 104.99 18:00:34
Open Price Low Price High Price Close Price Prev Close
104.28 102.115 108.565 104.99 105.39
Bid Price Ask Price Spread News
91.12 110.00 18.88 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,344 382,388 $ 104.04 $ 39,781,881 616,512 56.64 - 179.647
Last Trade Time Type Quantity Stock Price Currency
17:16:26 formt 620 $ 104.99 USD

Ultragenyx Pharmaceutical Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 6.95B 66.16M 49.64M $ 103.71M $ -93.93M -7.12 -32.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Ultragenyx Pharmaceutical News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RARE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week102.47111.675101.44107.44323,9342.522.46%
1 Month121.03123.559999.61109.18435,832-16.04-13.25%
3 Months147.67175.0099.61128.79416,991-42.68-28.9%
6 Months91.26179.64786.8481128.92478,71513.7315.04%
1 Year58.05179.64756.64103.32457,58146.9480.86%
3 Years53.68179.64731.9971.91502,47551.3195.58%
5 Years70.39179.64731.9967.78498,88834.6049.15%

Ultragenyx Pharmaceutical Description

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.